Liam Condon, president of the Crop Science division at Bayer, isn’t like most company presidents. When rumors of mergers and acquisitions were swirling, he was itching to talk to media. That’s how excited he was about the potential match with Monsanto. When asked about the deal and why Bayer acquired  Monsanto, his response was that the two companies share similar goals and views. The ability to leverage the combination of research and development would lead to more innovation for farmers, says Condon. Condon says he hopes the combination will create a customizable product portfolio with a comprehensive offering of seed and crop-protection products, a leading platform in digital farming, and leading innovation capabilities and R&D technology platforms. Today, Monsanto and Bayer both spend between 10% and 11% of sales on research and development. Combined, that’s $2.8 billion. My assumption, moving forward, is that level should be maintained, but we can achieve a lot more innovation together than as separate entities. It is about getting more out of R&D and getting more innovation to growers faster. We won’t do that by cutting back on R&D. It will be the focused area...